Search

Aim. To identify predictors of cardiovascular events (CVEs) in patients with heart failure (HF) and P. aeruginosa pneumonia.Material and methods. The study included 92 patients with HF with mildly reduced or reduced ejection fraction and nosocomial pneumonia. Based on sputum or bronchoalveolar lavage microbiological examination, patients were divided into 2 following groups: group I — 51 patients with HF and P. aeruginosa pneumonia, group II — 41 patients with HF and pneumonia caused by other pathogens (Staphylococcus aureus, Streptococcus pneumoniae). During the hospital stay, the following morbidities were assessed: cardiovascular death, acute coronary syndrome, non-fatal cerebrovascular accident, pulmonary embolism, lower extremity venous thrombosis.Results. CVEs were significantly more often observed in patients with HF and P. aeruginosa pneumonia — 30 (58,8%) than in patients with HF and pneumonia caused by S. aureus or S. pneumoniae — 5 (12,1%). Complete blood count in group I patients revealed a decrease in hemoglobin level to 114 [95; 133] g/l, when compared with patients in group II — 139 [118; 150] g/l (p11×109/l (RR 2,412; 95% CI 1,399-4,158; p=0,048), CRP >133 mg/l (RR 3,115; 95% CI 1,611-6,025; p

The article presents the main mechanisms of development of lipid metabolism disorders and endothelial dysfunction in patients with hypertension (HTN) and type 2 diabetes (T2D), and their contribution to cardiovascular events. Modern approaches to the treatment of hypertension and dyslipidemia in people with type 2 diabetes are considered from the standpoint of the latest clinical guidelines, focusing on fixed-dose combinations as a means of an integrated approach to managing risk factors in comorbid patients. Data are presented on the efficacy and safety of fixed-dose combination of lisinopril, amlodipine and rosuvastatin in patients with hypertension and T2D.

The purpose of this study was evalueted of a long-term treatment outcome in chronic myeloid leukemia (CML) patients in accelerated phase treated with GlivecR and determination of an optimum therapy schedule. 105 patients (men — 46, women — 59) at the age from 15 till 74 years (a median age — 40 years) enrolled between 02.2001 and 02.2007 were studied. Treatment started a dose of 600 mg/day. At the insufficient primary therapy response or loss complete hematological and/or complete cytogenetic remission in the course of treatment, dose have been increased to 800 mg/day. In 82 (78.1%) patients complete hematological remissions have been reached. In 44 (41.9%) patients complete cytogenetic response (CR) is received, and in 27 (61.4 %) of them with molecular response: complete — 17 (63%) and major — 10 (27%). 6-year overall survival rate (OS) was 61.9%, 6-year event-free survival rate (EFS) — 30.5%. Achievement of complete CR was a predictor of long longterm survival rate: OS — 95.5% versus 37.7 % (р

Hypertension and dyslipidemia are key risk factors for cardiovascular disease. Despite the currently existing possibilities for the combined use of various classes of antihypertensive and lipid-lowering drugs, the problem of treating patients with a high risk of cardiovascular events has not lost its significance and its solution in a specific clinical situation often remains very difficult. The review analyzes current data on the efficacy and safety of the fixed-dose combination of lisinopril, amlodipine and rosuvastatin to solve the problem of a personalized approach in the treatment of comorbid patients with a high risk of car­diovascular events.

Failure to achieve blood pressure targets and insufficient control are important cardiology problems that remain relevant despite well-defined and generally available modern algorithms for the treatment of hypertension (HTN) and the availability of effective antihypertensive drugs. The level of hypertension control in Russia remains quite low and is 14,1% for men and 30,9% for women. The generally recognized most important factor determining the low blood pressure control is non-compliance with antihypertensive therapy, which, in turn, determines the high percentage of uncontrolled HTN among patients. The review discusses the most common causes of low adherence to treatment. Particular attention is paid to the doctor’s ability to remove barriers to adherence and errors in the choice of therapy, including insufficient prescribing of fixed-dose combinations. The review presents a modern view on the significance of combined antihypertensive therapy. Atten­tion is focused on fixed-dose combinations of antihypertensives, the use of which significantly increases adherence to therapy, and the unique properties and effectiveness of lisinopril, amlodipine and indapamide are described.

The paper proposes an approach to development of a mathematical model for subsequent optimization and control over a complicated technological object. The combined model makes it possible to use advantages of experimental-statistic and determined approaches for provision of high adequacy, easy adaptability and wide range of application. The approach has been used for development of a three-shell gas reactor model for ammonia production